Notably, high expression of CysLT1R was associated with poor prognosis in CRC patients and reduced survival and stemness in colorectal and breast cancer [14,16,17], while CysLT2R has been reported to have an antitumorigenic effect in CRC patients and cell lines [14,35]. This evidence concerns the gene CYSLTR2 and colorectal carcinoma.